Cover Image
市場調查報告書

急性淋巴性白血病治療藥的全球市場:2015年∼2019年

Global Acute Lymphocytic Leukemia Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 345156
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
急性淋巴性白血病治療藥的全球市場:2015年∼2019年 Global Acute Lymphocytic Leukemia Therapeutics Market 2015-2019
出版日期: 2015年11月11日 內容資訊: 英文 65 Pages
簡介

全球急性淋巴性白血病治療藥市場預測從2014年到2019年間將以4.52%的年複合成長率擴大。

本報告依各地區提供全球急性淋巴性白血病治療藥市場現狀與今後的預測,加上同疾病概要,市場成長因素與課題,主要供應商分析等資訊。

第1章 摘要整理

  • 概況

第2章 本報告的調查範圍

  • 市場概要
  • 主要供應商的產品

第3章 產品簡介

第4章 市場調查手法

  • 調查手法
  • 經濟指標

第5章 簡介

  • 主要市場洞察

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 疾病概要

  • 病因和風險因素
  • 病理學
  • 症狀
  • 流行病學
  • 分類
  • 診斷
  • 治療和管理

第8章 各藥物給藥途徑的市場分類

  • 口服
  • 非口服

第9章 各分子類型的市場分類

  • 生技藥品
  • 小分子

第10章 地理區分

  • 全球急性淋巴性白血病治療藥市場:各地區
  • 南北美洲
  • 歐洲·中東·非洲地區
  • 亞太地區

第11章 市場成長因素

第12章 市場成長因素的影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第17章 主要供應商分析

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

第18章 附錄

  • 簡稱清單

第19章 關於Technavio

目錄
Product Code: IRTNTR7891

Covering: An in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, Bristol-Myers Squibb, and Novartis.

Market landscape of acute lymphocytic leukemia

Acute lymphocytic leukemia or acute lymphoblastic leukemia, is a malignancy of the blood cells that affects the lymphoblasts or leukemic blasts, which witnesses an uncontrolled cell division. The main symptoms a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding.

Currently, the disease cannot be cured completely but the risk can be reduced by administering medication.

Technavio's market research analysts expect the global acute lymphocytic leukemia market to grow at a steady rate and post a CAGR of over 4% during the forecast period. One of the major factors contributing to the growth of the market is the provision for orphan drugs. For instance, in the US, orphan designation for a drug means incentives like tax credits for qualified clinical testing, exemption from prescription drug user fees unless indicated for additional non-orphan indications, and market exclusivity for seven years.

Segmentation of the acute lymphocytic leukemia market by route of administration

  • Oral
  • Parenteral

Many medications are administered through the oral route to guarantee a systemic effect. The oral route is a sub-division of enteral administration and is considered to be one of the safest and most preferred routes of drug administration.

Geographical segmentation of the acute lymphocytic leukemia market

  • Americas
  • APAC
  • EMEA

With a share of over 49%, the Americas dominated the acute lymphocytic leukemia market, with the US being the major revenue contributor. The Americas is closely followed by the EMEA and the APAC region and the market is expected to follow a similar trend during the forecast period.

Competitive landscape and key vendors

The acute lymphocytic leukemia market is marked by the presence of both global and local drug manufacturers with varied product portfolios containing generic and off- label drugs as well as branded therapies. Besides, the high level of unmet medical need is expected to give a platform to the vendors to develop products to cater to relevant areas and enhance their market shares.

Primary vendors in this market are -

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

Other prominent vendors included in this report are Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sigma-Tau Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2019?
  • What are the key factors driving the global acute lymphocytic leukemia market?
  • What are the key market trends impacting the growth of the global acute lymphocytic leukemia market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global acute lymphocytic leukemia market?
  • What are the market opportunities and threats faced by the vendors in the global acute lymphocytic leukemia market?
  • What are the trending factors influencing the market shares of the Americas, EMEA, and APAC?
  • What are the key outcomes of the five forces analysis of the global acute lymphocytic leukemia market?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Introduction

  • Key market highlights

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Disease overview

  • Etiology and risk factors
  • Pathophysiology
  • Symptoms
  • Epidemiology
  • Classification
  • Diagnosis
  • Treatment and management

PART 08: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 09: Market segmentation by type of molecules

  • Biologics
  • Small molecules

PART 10: Geographical segmentation

  • Global acute lymphocytic leukemia therapeutics market by geography 2014
  • Acute lymphocytic leukemia market in Americas
  • Acute lymphocytic leukemia market in EMEA
  • Acute lymphocytic leukemia market in APAC

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis
  • Other prominent vendors

PART 17: Key vendor analysis

  • Amgen
  • Bristol-Myers Squibb
  • Novartis

PART 18: Appendix

  • List of abbreviation

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global acute lymphocytic leukemia therapeutics market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global acute lymphocytic leukemia therapeutics market by geography 2014
  • Exhibit 05: Global acute lymphocytic leukemia therapeutics market revenue by geography 2014-2019 ($ millions)
  • Exhibit 06: Global acute lymphocytic leukemia therapeutics market revenue by geography (percentage)
  • Exhibit 07: Acute lymphocytic leukemia market in Americas 2014-2019 ($ millions)
  • Exhibit 08: Acute lymphocytic leukemia market in EMEA 2014-2019 ($ millions)
  • Exhibit 09: Acute lymphocytic leukemia market in APAC 2014-2019 ($ millions)
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Impact of drivers and challenges
  • Exhibit 12: Key takeaways: Amgen
  • Exhibit 13: Global sales of Sprycel 2012-2014 ($ millions)
  • Exhibit 14: Key takeaways: Bristol-Myers Squibb
  • Exhibit 15: Global sales of Gleevec/Glivec 2012-2014 ($ millions)
  • Exhibit 16: Key takeaways: Novartis
  • Exhibit 17: Amgen: Business segmentation by revenue 2014
  • Exhibit 18: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 19: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 20: Business segmentation by revenue 2013 and 2014 ($ billions)
Back to Top